Genzyme sues Impax over Renvela ANDA
This article was originally published in Scrip
Executive Summary
Genzyme has filed a patent infringement suit in the US District Court for the District of Maryland against Impax Laboratories regarding its submission of an ANDA for a generic version of the phosphate binder Renvela (sevelamer carbonate) 800mg tablets, thus triggering a 30-month Hatch-Waxman stay of approval while the legal challenge is fought.